Monitor for any announcement of a reverse stock split or transfer application to Nasdaq Capital Market within the 180-day period. Failure to regain compliance by April 21, 2027 would trigger delisting proceedings, though the company may appeal.
Price Chart
Executive Summary
Milestone Pharmaceuticals received a Nasdaq deficiency notice on October 23, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days on the Nasdaq Global Select Market. The company has a 180-day cure period until April 21, 2027, and is considering options including a reverse stock split or transfer to the Nasdaq Capital Market to regain compliance.
Key Facts
- Received Nasdaq deficiency notice on October 23, 2026 for bid price below $1.00 for 30 consecutive business days
- 180-day compliance period expires April 21, 2027
- Must close at $1.00 or more for 10 consecutive business days to regain compliance
- May transfer to Nasdaq Capital Market for additional cure period if eligible
- Considering reverse stock split as a potential cure option
- Market cap approximately $80 million as of analysis time
Financial Impact
Delisting risk could severely reduce institutional ownership and liquidity; $80M market cap at risk
Risk Factors
- Potential delisting from Nasdaq if compliance not regained by April 21, 2027
- Reverse stock split may be necessary but could face shareholder resistance
- Delisting would severely reduce institutional ownership and liquidity
- No assurance of successful transfer to Nasdaq Capital Market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-119669 |
| Document: 0001104659-26-119669-index-headers.html | 0001104659-26-119669 |
| Document: 0001104659-26-119669-index.html | 0001104659-26-119669 |
| Document: 0001104659-26-119669.txt | 0001104659-26-119669 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 4d ago | 8-K | $0.7896 | awaiting T+20 | awaiting T+20 | $0.7300 (+7.55%) |
Sep 3, 2026 8w ago | 8-K | $1.20 $0.7794 | ▼ −35.05% | ▼ −35.65% | $0.7300 (−39.17%) |
Aug 21, 2026 10w ago | Press Release | $1.06 $0.9178 | ▼ −13.00% | ▼ −12.48% | $0.7300 (−30.81%) |
Aug 12, 2026 11w ago | 8-K | $1.13 $1.05 | ▲ +6.67% | ▲ +4.77% | $0.7300 (+35.11%) |
May 26, 2026 22w ago | EFFECT | $1.40 $1.28 | ▲ +8.57% | ▲ +6.62% | $0.7300 (+47.86%) |
May 13, 2026 24w ago | S-3 | $1.63 $1.27 | ▲ +22.09% | ▲ +21.23% | $0.7300 (+55.21%) |
May 13, 2026 24w ago | 8-K | No price | awaiting T+20 | awaiting T+20 | No price |
May 13, 2026 24w ago | Press Release | $1.72 $1.27 | ▼ −26.16% | ▼ −25.55% | $0.7300 (−57.56%) |
Mar 20, 2026 32w ago | Press Release | $1.36 $2.04 | ▲ +50.00% | ▲ +40.68% | $0.7300 (−46.32%) |
Mar 16, 2026 32w ago | Press Release | $1.69 $2.03 | ▲ +20.12% | ▲ +16.34% | $0.7300 (−56.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers